E35: Biogen's controversial Alzheimer's drug approval, the billionaire space race, real estate, Bitcoin & more
All-In with Chamath, Jason, Sacks & Friedberg
00:00
The Controversy of Alzheimer's Drug Approval
This chapter examines the recent FDA approval of Biogen's controversial Alzheimer's drug, the first new treatment in nearly two decades. It discusses the drug's limitations, the ethical dilemmas surrounding its high pricing, and the tensions between innovation and regulation in the pharmaceutical industry. The conversation further explores the implications for patients, caregivers, and healthcare systems as they navigate the uncertain landscape of medication efficacy and cost.
Transcript
Play full episode
